BUY Aurobindo Pharma — Arun Kumar Mantri, 28 Aug 2026

byArun Kumar MantriHorizon: BTST28 Aug 2026, 3:14 pm ISTvia CNBC Awaaz.

Entry₹1,645.3Inferred

Target₹1,692

Stop loss₹1,640-0.32% risk

Exit₹1,64031 Aug 2026, 9:33 am

Stop-loss hit-0.32%

Follow Arun Kumar Mantri for new calls(17% target hit, 65 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 4 active BTST picks this session

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 31 Aug 2026

3 supporting2 neutral2 opposing

Supports the BUY call (3)

2 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·31 Aug · today

Aurobindo Pharma Share Price Gains As USFDA Concludes Inspection At Subsidiary Lannett's Unit

NewsNdtv-Profit·24 Aug · 6d ago

Aurobindo Pharma US FDA inspection ends with one observation at AuroPeptides facility

NewsCnbc-Tv18·21 Aug · 1w ago

Neutral / worth noting (2)

Aurobindo Pharma’s API plant gets three US FDA observations after inspection

NewsCnbc-Tv18·28 Aug · 2d ago

Here's why these four pharma stocks are in focus today

NewsCnbc-Tv18·24 Aug · 1w ago

Weighs against the BUY call (2)

USFDA Issues Three Observations To Aurobindo Pharma Arm's Facility In Andhra

NewsNdtv-Profit·28 Aug · 2d ago

Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA

NewsLivemint·24 Aug · 6d ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.